Find public news by keyword, exact ticker, category and date.
Open a ticker page for its news coverage. The news search below stays a text search.
2 results loaded, newest first. End of these results.
Monte Rosa Therapeutics announced positive data from a phase 1 study of MRT-8102, a molecular glue degrader being developed for inflammatory conditions in patients at elevated risk of cardiovascular disease.
Monte Rosa Therapeutics announced positive GFORCE-1 Phase 1 results for MRT-8102, demonstrating approximately 80-90% NEK7 degradation and broad normalization of ASCVD pathogenic drivers, accompanied by a favorable safety profile.